RxDoctor Payments Data

Katarzyna Hause-Wardega, MD

Internal Medicine · Cleveland, OHNPI 1720019649

Payments from drug & device makers

$274in general payments, 2019–2025

Across 17 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$74
  • Novo Nordisk$39
  • AbbVie$37
  • Johnson & Johnson$34
  • Abbott$19
  • SK Life Science, Inc.$16
  • plus $55 from 4 others

What the payments were for

  • Food & beverage$274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$274 in reported general payments places this provider in the 55th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$76,582
Medicare patients
235
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban284$191,255
JardianceEmpagliflozin151$146,314
TrulicityDulaglutide53$74,415
JanuviaSitagliptin Phosphate74$70,159
OzempicSemaglutide53$69,450
XareltoRivaroxaban71$45,229
FarxigaDapagliflozin Propanediol33$26,748
MyrbetriqMirabegron63$23,929
CreonLipase/Protease/Amylase17$20,624
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$18,634
Lantus SolostarInsulin Glargine,hum.Rec.Anlog100$12,958
RestasisCyclosporine31$10,943
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$10,428
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,636
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$9,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Pradaxa$13$157,097178 claims
Novo NordiskOzempic$39$69,45053 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort$74$45,72477 claims
Johnson & JohnsonXarelto$34$45,22971 claims
AbbVieCreon, Restasis, Combigan$37$34,24461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →